EU CHMP issues negative opinion on Apellis MAA application for pegcetacoplan (Syfovre) injection

News
Article

Apellis will seek re-examination from the CHMP following the opinion

The European Medicines Agency (EMA) website is displayed on a phone and a computer. Image credit: ©Brenda Blossom – stock.adobe.com

Apellis stated it plans on seeking re-examination of pegcetacoplan and a final opinion is expected in the fourth quarter of 2024. Image credit: ©Brenda Blossom – stock.adobe.com

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has again recommended the refusal of marketing authorisation for Syfovre (pegcetacoplan), according to a press release from Apellis Pharmaceuticals.1 The first negative marketing authorisation application (MAA) opinion came earlier this year in January. At the time, Apellis stated it was expecting the negative outcome based on a “negative trend vote following an oral explanation meeting in December 2023.”

The most recent refusal was issued by the CHMP2 with the explanation that, while Syfovre did slow the growth of GA lesions, it “did not lead to clinically meaningful benefits for patients.” The committee further explained by stating, “It was noted that benefits of a treatment should impact patients’ everyday functioning, and this was not demonstrated in the studies. In terms of safety, regular injections into the eye carry a significant risk of adverse events, including the development of other forms of AMD or inflammation in the eye, that could further worsen vision.” Because of this, the CMHP stated “a positive balance of benefits and risks of Syfovre in the treatment of geographic atrophy caused by AMD could not be established” and therefore recommended a rejection.

The studies mentioned in the statement from the CHMP were the OAKS and DERBY multi-centre, 2-year, Phase 3, randomised, double-masked trials.

Apellis stated it plans on seeking re-examination of pegcetacoplan3 and a final opinion is expected in the fourth quarter of 2024. The company noted there were "multiple dissenting votes by CHMP members" in regards to the issued MAA opinion. Furthermore, an Ad Hoc Expert Group meeting took place in which experts agreed that size of GA lesion is an acceptable primary outcome measure for a trial in GA and that microperimetry is the best available functional measure in GA.

“We remain steadfast in our commitment to GA patients in Europe who have no treatment for this devastating disease, which leads to irreversible vision loss,” said Jeffrey Eisele, PhD, chief development officer at Apellis. “It is encouraging to see the broad support for pegcetacoplan within the European retina community, and we are focused on promptly initiating the re-examination to bring this important treatment to those in need.”

Syfovre was approved by the US FDA in February of 2023 to treat GA secondary to AMD.

References:

  1. Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application. Press Release. Published 26 January, 2024. Accessed 1 July, 2024. https://investors.apellis.com/news-releases/news-release-details/apellis-announces-negative-chmp-opinion-pegcetacoplan-ga
  2. Refusal of the marketing authorisation for Syfovre (pegcetacoplan). June 28, 2024. Accessed 1 July, 2024. https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-syfovre_en.pdf
  3. Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU. Published 28 June, 2024. Accessed 1 July, 2024. https://investors.apellis.com/news-releases/news-release-details/apellis-plans-seek-re-examination-following-negative-chmp

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.